Navigation Links
Microbix Sales Grow Over 30% In The Second Quarter; Up 43% In The First Half '09
Date:5/14/2009

A potential investor has agreed in principle to lead the fundraising efforts subject to finalization of the deal structure.

Semen Sexing Technology (SST)

In the SST program, Microbix focused on strengthening its intellectual property position. "We concluded the research phase of the program in the second quarter," said Mr. Gastle. "The results led to a conclusion which brings the market opportunity closer with more certainty and also provides a significant competitive advantage over existing technology. It will give the Company a strong patent position in a $ 3 billion artificial insemination market which has no regulatory barrier to entry." The Company is currently evaluating non-dilutive ways to advance the product.

Urokinase

The Company acquired all Urokinase assets from ImaRx Therapeutics, Inc. of Tucson, Arizona, (Nasdaq: IMRX) in September 2008. These assets included ImaRx' remaining Urokinase inventory as well as the regulatory file for the product (formerly known as Abbokinase(R), now rebranded as Kinlytic(R)), key raw materials for Urokinase manufacturing, and the corresponding sales and marketing infrastructure.

The anticipated launch of the drug Kinlytic has been delayed due to the ongoing review by the FDA of the Company's request for the release of this Urokinase product for distribution in the US market. The company is preparing to file an appeal that will be submitted in the third quarter. "There are no problems with the safety and efficacy of this drug. Concerned physicians are asking for Urokinase supply on a daily basis," Mr. Gastle explained. Microbix is one of many drug companies that are experiencing delays at the FDA today and continues to press matters with the agency," said Mr. Gastle. "We are optimistic that ultimately we will reach the market" he said.

Ot
'/>"/>

SOURCE Microbix Biosystems Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. ImaRx Therapeutics Signs Letter of Intent With Microbix Biosystems for the Sale of Urokinase
2. Microbix Uses Core Business Cashflow To Fund Late-Stage Pipeline To Build Shareholder Value In 2009
3. Microbix First Quarter Sales Grow Over 50% With Continued Progress On The Pipeline
4. Microbix Announces A New Technology Platform For The SST Project
5. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
6. Pathway Medical Technologies Adds Joe Rafferty as VP, Sales, and Moves To Larger Facility to Accommodate Rapid Growth
7. International Isotopes Inc. Announces Completion of an Exclusive Distributor Agreement for Sales of New Style Transportation Containers
8. Kline Study: Better Brushing Habits Boost European Oral Care Sales
9. BioElectronics Corporation Announces Singapore and Malaysia Sales
10. Thermo Fisher Scientific Acquires Instrument Sales Business of Davis Inotek
11. AMDLs Jade Pharmaceutical Subsidiary Announces New Product Strategy; Six New Products, Including One With Sales Projected at Upwards of $10 Million, Under Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... San Diego, CA (PRWEB) January 14, 2014 ... based on the products of cells grown under simulated ... an international license agreement with Suneva Medical, Inc. for ... media (CCM). , This agreement is an ...
(Date:1/14/2014)... EquitiesIQ, a leading informational research provider, ... is an emerging biomedical company acquiring, developing, manufacturing, and ... , Free report download: http://equitiesiq.com/reports/alliqua/ , In ... team and Board, which launched the company’s new strategy ...
(Date:1/14/2014)... iLab Solutions, the leader in core facility management software, ... Strategy. In this role, Michelle will work with current and ... the development of iLab products. Her main goal will be ... the scientific community by offering the most advanced, user-friendly, and ...
(Date:1/14/2014)... Global Record Systems, LLC, (GRS), ... solutions for patients, physicians, the biopharmaceutical industry, regulators, ... the signing of a three-year Research Collaboration Agreement ... (FDA). This initiative is designed to generate ...
Breaking Biology Technology:Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 3EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3iLab Solutions Announces Michelle Detwiler as the New Director of Product Strategy 2Global Record Systems Announces Research Collaboration Agreement with FDA to Create a Novel “Big Data” Paradigm for Collection of Patient Safety and Outcomes Information 2
... Spherix Incorporated (Nasdaq: SPEX ), an ... and atherosclerosis; and providers of technical and regulatory consulting ... announced that it will host an investment community conference ... December 9, to discuss results of the Company,s Phase ...
... 6, 2010 Viruses have a bad rep—and rightly ... precisely replicate itself makes it a destructive scourge to ... researchers at the University of Maryland,s A. James Clark ... Resources, brought together by Professor Reza Ghodssi, is turning ...
... Todd Hutchings has assumed leadership of Egon Zehnder ... who led the practice, will continue at the firm ... executives. In his new role, Mr. Hutchings ... with boards and providing the full array of functional ...
Cached Biology Technology:Spherix to Hold Business Update Conference Call December 9, 2010 at 4:30 p.m. Eastern Time 2Bad Virus Put to Good Use: Breakthrough Batteries 2Bad Virus Put to Good Use: Breakthrough Batteries 3Bad Virus Put to Good Use: Breakthrough Batteries 4Bad Virus Put to Good Use: Breakthrough Batteries 5Bad Virus Put to Good Use: Breakthrough Batteries 6Egon Zehnder International Names Todd Hutchings to Lead Life Sciences Practice Group 2
(Date:4/16/2014)... of Nicaragua,s legal, artisanal green sea turtle fishery has ... of turtles in what may have become an unsustainable ... Society and University of Florida. , During the research ... turtles were killed between 1991 and 2011, with catch ...
(Date:4/16/2014)... Florida State University researchers have identified a new ... bone density and muscle mass with obesity. , "It ... were the better your bones would be because the ... Hazel Stiebeling Professor of Nutrition at Florida State. "But, ...
(Date:4/16/2014)... eyes up, and you cannot lift your upper eyelid. You walk ... look straight when they are rolled down in the eye socket. ... normal position of their head. In order to correct this condition, ... paper published in the April 16 print issue of the journal ...
Breaking Biology News(10 mins):Declining catch rates in Caribbean green turtle fishery may be result of overfishing 2Declining catch rates in Caribbean green turtle fishery may be result of overfishing 3Researchers: Obesity can amplify bone and muscle loss 2Researchers track down cause of eye mobility disorder 2
... as a model to study embryo formation, scientists report ... of a protein called Bicoid is vital to normal ... by the journal Dec. 19, the study shows how ... identified protein the researchers named Fates-shifted (Fsd). Without the ...
... Society has announced the winners of its second annual ... Annual Meeting at the Baltimore Convention Center in Baltimore, ... Professional Opportunities for Women, has initiated these travel fellowships ... their participation at the Meeting. The recipients of ...
... The prolonged, extensive emission of greenhouse gases over ... ocean life, according to a study by UC Merced ... emissions exacerbated by the burning of fossil fuels ... more acidic, and Beman,s study shows that the increased ...
Cached Biology News:Fruit fly study digs deeper into poorly understood details of forming embryos 2Biophysical Society announces winners of 2011 CPOW Travel Awards 2Rising greenhouse gases profoundly impact microscopic marine life 2
Newborn Calf Serum US Origin...
SPDP-Trinitrophenol (TNP) Bovine Serum Albumin...
Acrylamide, 500 g. Assay: > 99.9%, acrylic acid: < 0.001%. Conductivity (35%): < 2 umhos/cm.Risks: 45, 46, 48, 23, 24, 25 ; Safety Precautions: 53, 44. Category: Nucleotides & Enzymes & Biochemicals...
HRP Monoclonal-Goat Diluent - 5X Concentrate, 25 mL...
Biology Products: